Last week, the FDA held a 2-day public hearing on “Manufacturer Communications Regarding Unapproved Uses of Approved or Cleared Medical Products.” The meeting addressed the longstanding disagreement between the FDA and medical product manufacturers regarding the communication of off-label information.

The dispute stems from the fact that physicians are allowed to prescribe a medicine or administer treatment for an unapproved use, but drug and medical device makers’ are not able to share the scientific information gathered from those unapproved uses. The chief concern (understandably so) is that public health may be compromised if a company communicates an unapproved use that has not been confirmed as safe or effective. Companies have called for the FDA and congress to reconsider these regulations—and last week, they were given the opportunity to proclaim it in person.

But judging by several recaps and social media activity, the input that the FDA heard Wednesday mostly leaned against allowing medical product manufacturers to market off-label products.

While the meeting was a welcome first step in improving lines of communication between industry and the FDA…

…the general sentiment on Twitter demonstrates that HCPs, patients and researchers alike are weary, if not in direct opposition, of change.

Be on the lookout for posts in the coming weeks – we will continue share insights on possible outcomes of last week’s hearing.